PROCTER & GAMBLE Co executive Susan Street Whaley reported both a stock sale and an equity award. On February 19, 2026, she completed an open-market sale of 1,809 shares of common stock at an average price of $159.4551 per share.
After this sale, her directly held common stock position was 30,215.0293 shares. She also had 6,589.6417 shares held indirectly through a retirement plan trustee. On February 17, 2026, she acquired 11.485 restricted stock units at no cost, increasing her RSU balance to 65.1290 units, which are scheduled to settle in Procter & Gamble common stock, generally in connection with retirement.
Morgan Stanley Smith Barney LLC files a Form 144 reporting proposed sales of Procter & Gamble common stock. The notice lists 1,400 shares tied to a Restricted Stock Unit Award dated 10/01/2021 and 1,493 shares from a Performance Stock Program Award dated 08/19/2024.
Procter & Gamble's Chief Research, Development & Innovation Officer, Aguilar Moses Victor Javier, exercised stock options and sold shares on February 13, 2026. He exercised 15,169 stock options at an exercise price of $91.07 per share, receiving the same number of common shares.
On the same day, he sold 15,169 common shares in an open-market transaction at a weighted average price of $162.2789 per share, within a price range of $162.26 to $162.311. Following these transactions, he held 44,735.4826 common shares directly, plus additional indirect holdings through a retirement plan and an international stock ownership plan.
Procter & Gamble’s Chief Human Resources Officer, Purushothaman Balaji, reported an option exercise and share sale on February 11, 2026. He exercised a stock option for 12,827 shares of common stock at an exercise price of $91.07 per share.
On the same day, he sold 12,827 common shares in an open-market transaction at a weighted average price of $160.3093 per share, as disclosed in the footnote. Following these transactions, he held 12,638.8004 shares directly and 5,223.363 shares indirectly through a retirement plan trustee.
Procter & Gamble executive chair Jon R. Moeller, who also serves as a director, reported option exercises and share sales in February 2026. On February 11, he exercised options for 11,036 common shares at $113.23 and sold 11,036 shares at $160. On February 12, he exercised options for 162,232 shares at $113.23 and sold 162,232 shares at a weighted average price of $162.4486. After these transactions, he directly holds 319,384.99 common shares, plus indirect holdings of 25,001.0511 shares through retirement plan trustees and 35,421.5707 shares held by his spouse.
Procter & Gamble CEO – Grooming Gary A. Coombe reported multiple equity transactions in Procter & Gamble common stock. On February 12, 2026, he exercised stock options for 36,093 shares at an exercise price of $78.52 per share, receiving the same number of common shares.
On the same date, he then sold 36,093 common shares in open-market transactions at a weighted average price of $162.3307, leaving 34,993.7893 shares of directly held common stock. He also reports indirect holdings of 486.4342 shares through a retirement plan trustee and 1,295.35 shares through an international stock ownership and pension plan.
In addition, previously granted restricted stock units, including 63.6893 units awarded on November 17, 2025, total 1,117.3663 RSUs. Footnotes explain that these RSUs and some share totals include dividend equivalents and may be delivered in shares upon retirement under the company’s programs.
The Procter & Gamble Company investor files a notice to sell restricted shares under Rule 144. The planned transaction covers 15,169 shares of common stock with an aggregate market value of $2,448,124.91, to be executed through Morgan Stanley Smith Barney LLC on the NYSE.
The shares were acquired and paid for in cash on 02/13/2026 through an exercise and sale of stock options. The filing also notes that Procter & Gamble had 2,324,000,685 shares of common stock outstanding, providing context for the size of this proposed sale.
An insider of Procter & Gamble plans to sell 12,827 shares of common stock under Rule 144. The planned sale has an aggregate market value of $2,022,176.55 and is scheduled for 02/11/2026 on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The shares will come from the exercise and sale of a stock option, paid in cash on 02/11/2026. The filing notes that Procter & Gamble has 2,324,000,685 common shares outstanding, which provides scale for the size of this planned transaction.
The Procter & Gamble Company has a shareholder filing a notice of proposed sale of 173,268 shares of common stock, with an aggregate market value of $27,315,700.20. The planned sale is tied to the exercise and sale of a stock option on 02/11/2026.
The shares are to be sold for cash through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The filing notes total common shares outstanding of 2,324,000,685 and includes a representation that the seller is not aware of undisclosed material adverse information about Procter & Gamble.
A holder of Procter & Gamble common stock has filed a notice of proposed sale under Rule 144. The filer plans to sell 2,215 shares of common stock with an aggregate market value of $352,185.00 and an additional 558 shares valued at $88,722.00. Both transactions are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, with an approximate sale date of February 10, 2026. The securities to be sold were originally acquired as restricted stock unit awards from The Procter & Gamble Company on March 1, 2022 and October 3, 2022.